The 10-Year Extended Follow-up of the DACAB Trial

The 10-Year Extended Follow-up of the Different Antiplatelet Strategies After Coronary Artery Bypass Grafting Trial

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07480629

Acronym

DACAB-FE-10Y

Enrollment

500

Registered

2026-03-18

Start date

2026-03-15

Completion date

2026-07-30

Last updated

2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiplatelet Therapy of Coronary Artery Bypass, CABG, Coronary Artery Disease

Keywords

Coronary Artery Bypass Grafting (CABG), Antiplatelet Therapy, Ticagrelor, Aspirin, Dual Antiplatelet Therapy (DAPT), Major Adverse Cardiovascular Events (MACE), Long-Term Follow-Up, DACAB, DACAB-FE

Brief summary

The goal of this observational study is to learn about the very long-term effects of different antiplatelet strategies in patients who underwent coronary artery bypass grafting (CABG) and participated in the original DACAB trial. The main questions it aims to answer are: Does one year of treatment with ticagrelor plus aspirin (dual antiplatelet therapy) after CABG reduce the risk of major adverse cardiovascular events (MACE) over 10 years compared with aspirin alone or ticagrelor alone? What are the long-term safety outcomes, including major bleeding events, among patients who received different antiplatelet strategies? Researchers will compare the three originally randomized groups (ticagrelor plus aspirin, ticagrelor alone, and aspirin alone) to see if a one-year course of dual antiplatelet therapy provides a sustained clinical benefit over a decade. Participants will: Be contacted by telephone by the central study team for a one-time follow-up interview. Provide information about their current health status, any cardiovascular events (such as heart attack, stroke, or repeat revascularization procedures) that have occurred since the last follow-up. Report their current use of medications, including antiplatelet and other cardiovascular drugs. Allow researchers to request relevant medical records to verify any reported clinical events.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Original enrollment and randomization in the DACAB trial

Exclusion criteria

Who explicitly refuse to provide informed consent for the 10-year follow-up

Design outcomes

Primary

Measure	Time frame	Description
4-Point Major Adverse Cardiovascular Events (4P-MACE)	From randomization to completion of 10-year follow-up	Time from randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, or coronary revascularization.

Secondary

Measure	Time frame	Description
5P-MACE	From randomization to completion of 10-year follow-up	Time from original randomization to the first occurrence of a composite of all-cause death, myocardial infarction, stroke, coronary repeat revascularization, or other cardiovascular-related rehospitalization.
3P-MACE	From randomization to 10-year follow-up	Time from randomization to the first occurrence of a composite of cardiovascular death, myocardial infarction, or stroke.
All-Cause Death	From randomization to 10-year follow-up	Time from original randomization to death from any cause.
Cardiovascular Death	From randomization to 10-year follow-up	Time from original randomization to death from cardiovascular causes, including death of unknown cause.
Myocardial Infarction	From randomization to 10-year follow-up	Time from original randomization to the first occurrence of myocardial infarction.
Stroke	From randomization to 10-year follow-up	Time from original randomization to the first occurrence of stroke (including ischemic and hemorrhagic stroke).
Coronary Repeat Revascularization	From randomization to 10-year follow-up	Time from original randomization to the first occurrence of any post-procedural PCI or repeat CABG
Other Cardiovascular-Related Rehospitalization	From randomization to 10-year follow-up	Time from original randomization to the first occurrence of hospitalization due to other cardiovascular causes besides those included in 4P-MACE, such as unstable angina, heart failure, arrhythmia, aortic syndrome, or peripheral vascular disease.

Countries

China

Contacts

PRINCIPAL_INVESTIGATORQiang Z Zhao, MD

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

STUDY_DIRECTORYunpeng Zhu, MD